Business
AstraZeneca’s Breast Cancer Pill Stumbles in First-Line Trial — a Week After an FDA Nod
Camizestrant missed its main goal in the broad first-line SERENA-4 study, cooling expectations for a blockbuster hopeful even as the same drug had just earned an FDA approval in a narrower, biomarker-defined group.